when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Pluvicto · news · pharmadog

← back to Pluvicto

News mentioning Pluvicto

23 stories

10dITM neuroendocrine tumor drug spurned by FDA over manufacturing qualmsfiercebiotech

16dJ&J pharma leader to retire; Krystal slumps on gene therapy missbiopharma dive

17dFDA expands Pluvicto label, making it available to most metastatic prostate cancer patientsendpoints

17dCurium strikes up to $8B deal for radiopharma rival Lantheusfiercebiotech

18dRecon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvictoraps

29dNovartis scraps mid-stage radiopharma asset as Pluvicto soarsbiospace

Jul 21, 26Novartis climbs on upbeat drug sales as key readouts loombiopharma dive

Jul 21, 26Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsbiospace

Jul 21, 26Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’fiercebiotech

Jul 15, 26Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerendpoints

Jul 6, 26Novartis to acquire ADC developer in a deal worth up to $1.5Bbiopharma dive

Jun 8, 26Precision under pressure: Logistic solutions for nuclear medicine scalabilitybiopharma dive

Jun 4, 26Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storystat

Jun 3, 26STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeuticsstat

Jun 3, 26STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading datastat

Jun 3, 26STAT+: Legend Biotech emerged as a rare market winnerstat

Jun 3, 26Opinion: The medical-billing AI arms race between providers and insurancestat

Jun 3, 26STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patientsstat

Jun 3, 26Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.stat

Jun 2, 26STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trialstat

Jun 2, 26STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingstat

May 29, 26STAT+: The woman behind the world’s biggest longevity competitionstat

Apr 24, 26Novartis pulls Pluvicto prostate cancer label expansion filing in the EUendpoints